Role of Dopamine Transporter in Glucose Control

Not Applicable

Completed

• Conditions: Obesity
• Interventions: Other: Glucose injection/Normal saline injection

• Registration Number: NCT03466697
• Lead Sponsor: Pusan National University Hospital

Brief Summary

Healthy subjects will be enrolled in this study. Each subject will be scanned twice with F18-FP-CIT PET which is commercially available. F18-FP-CIT reflects dopamine transporter availability of striatum. Before each PET scan, subject will be injected either glucose or normal saline. Therefore, PET scan will reflect the changes of dopamine transporter availability after the injection of glucose.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-03-08
• Study First Submitted QC: 2018-03-13
• Study Start: 2018-03-14
• Study First Posted: 2018-03-15
• Primary Completion: 2021-12-20
• Study Completion: 2021-12-20
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-19
• Last Update Posted: 2022-04-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• healthy subjects

Read More

Exclusion Criteria

• known neurologic disorder
• known drug addiction
• known endocrine disorder

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Healthy subjects	Glucose injection/Normal saline injection	All subjects will be injected twice for each visit (normal saline or glucose)

Primary Outcome Measures

Name	Time	Method
Specific binding ratio of dopamine transporter availabilitiy measured from PET scans	less than 1 month	Specific binding ratio of dopamine transporter availabilitiy measured from PET scans

Trial Locations

Locations (1)

Pusan National University Hospital; 🇰🇷 Busan, Korea, Republic of